Context Therapeutics (NASDAQ:CNTX) Receives “Buy” Rating from D. Boral Capital

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Several other research analysts also recently commented on the stock. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. JMP Securities began coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a report on Monday, September 23rd. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $6.33.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $0.98 on Wednesday. Context Therapeutics has a 1 year low of $0.89 and a 1 year high of $2.75. The business has a fifty day simple moving average of $1.38 and a two-hundred day simple moving average of $1.89. The company has a market capitalization of $73.38 million, a P/E ratio of -1.08 and a beta of 2.10.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). As a group, analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Investors Weigh In On Context Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC increased its stake in Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after acquiring an additional 25,300 shares during the last quarter. Ally Bridge Group NY LLC grew its holdings in shares of Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after purchasing an additional 1,160,281 shares in the last quarter. Great Point Partners LLC purchased a new position in shares of Context Therapeutics during the second quarter worth about $14,876,000. Affinity Asset Advisors LLC increased its position in shares of Context Therapeutics by 392.4% in the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares during the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in Context Therapeutics in the second quarter valued at approximately $10,348,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.